VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
S-892216-PO
Phase 1
Small molecule
Shionogi
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Renal Impairment
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Renal Impairment
Phase 1
Completed
Clinical
Trials by Indication
[1]
Renal Impairment
1 trial
A Phase 1, Multicenter, Nonrandomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of S-892216-PO in Participants With Varying Degrees of Renal Impairment and Matched Control Participants With Normal Renal Function
Completed
·
Shionogi
·
Phase 1
·
NCT07217886
·
24 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for S-892216-PO. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
S-892216-PO compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for S-892216-PO. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Shionogi company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 1
[1]
Company
Shionogi
Related News
